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ENHANCED EXPRESSION OF HUMAN 
PLATELET-DERIVED GROWTH FACTOR IN 
PICHIA PAST ORIS 
STATEMENT OF GOVERNMENT SUPPORT 
The present invention Was supported in part by funds 
from the National Institutes of Health (Grant DK 45518). 
The Government may have certain rights in this invention. 
TECHNICAL FIELD 
The present invention relates to methods of protein 
production, puri?cation and characteriZation. The invention 
more particularly relates to the expression of platelet 
derived groWth factor (PDGF), especially in the yeast Pichia 
pastoris. 
BACKGROUND OF THE INVENTION 
Platelet-derived groWth factor (PDGF) is a potent mitogen 
and chemoattractant that plays critical roles in 
embryogenesis, cell differentiation and Wound repair. PDGF 
is a family of three disul?de-linked glycoprotein dimers of 
M, 29,000—32,000 that arise from stochastic assembly of the 
homologous subunits, A-chain and B-chain, yielding the 
heterodimer PDGF-AB and homodimers PDGF-AA and 
PDGF-BB [for a revieW, see ref. 1]. The A-chain is 
expressed as tWo different forms (“long” and “short”) as 
determined by alternative splicing, With the long form 
containing an extended carboxyl terminus of basic amino 
acids that mediates association With the extracellular matrix 
and is encoded by exon 6 The B-chain also contains a 
cationic carboxyl terminus that has been implicated in the 
strong association of PDGF-BB With the cell surface The activity of PDGF is mediated by Wo PDGF receptor 
isotypes, 0t and [3, Which upon ligand binding associate 
noncovalently to form homo- and heterodimers [4,5]. The 
PDGF ot-receptor has a high af?nity for both A- and 
B-chains, While the [3-receptor recogniZes only the B-chain 
[6] 
X-ray crystallographic analysis of recombinant human 
PDGF-BB has revealed an antiparallel arrangement of the 
disul?de-linked B-chain monomers Each B-chain 
monomer is characteriZed by a so-called “cysteine knot” 
structure, consisting of three intrachain disul?de bonds and 
tWo antiparallel [3-strands, interconnected by three loop 
segments (I—III). The cationic residues Arglsg, Lysl?o, 
Lys161 of the A-chain, Which correspond to the loop III 
region of the B-chain, are demonstrated as being required for 
high affinity receptor binding and mitogenic activity Furthermore, a synthetic peptide conta ning loop III residues 
157—163 of the B-chain exhibits PDGF antagoniZing activ 
ity [9], While a mutation at residue Lys161 of the B-chain is 
shoWn to interfere With high affinity binding to the 
ot-receptor [10]. 
The present invention concerns the transformation of 
Pichia pastoris With a cDNA encoding the PDGF B chain. 
Others have used the Pichia pastoris system to express 
proteins. For instance, US. Pat. No. 5,324,639 discloses the 
expression of insulin-like groWth factor-1 in Pichia pastoris 
cells. The recombinant protein is disclosed as being secreted 
into the culture medium at the level up to 100 times higher 
than results published in the literature using Saccharomyces 
cerevisae as the host cell. HoWever, the reference does not 
suggest expressing PDGF in this system. 
Cook et al., “Puri?cation and Analysis of Proteinase 
Resistant Mutants of Recombinant Platelet-Derived Growth 
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2 
Factor-BB Exhibiting Improved Biological Activity,” Bio 
chem. J. 281: 57—65 (1992) disclose the expression of 
recombinant platelet-derived groWth factor-BB and tWo 
protease-resistant mutants thereof in Saccharomyces cerevi 
siae. The expression construct utiliZed sequences encoding 
the yeast ot-factor pre-pro sequence upstream of the PDGF 
coding sequences to facilitate secretion. HoWever, secretion 
into the culture medium Was very loW and most of the PDGF 
remained intracellular. The authors state that “a major lim 
iting factor to PDGF-BB expression is, therefore, the secre 
tion of PDGF-BB into the medium.” 
Craig et al., “Characterization of the Structure and Con 
formation of Platelet-Derived GroWth Factor-BB (PDGF 
BB) and Proteinase-Resistant Mutants of PDGF-BB 
Expressed in Saccharomyces cerevisiae, ” Biochem. J. 281: 
67—72 (1992) disclose structural studies of the recombinant 
PDGF-BB produced in Cook et al. (above). The authors 
conclude that the protease-resistant mutants have the same 
secondary and tertiary structures as the Wild-type PDGF 
BB. The structure is reported to be considerably different 
than that reported for authentic PDGF-BB. 
Duan et al., “A Functional Soluble Extracellular Region 
of the Platelet-Derived GroWth Factor (PDGF) [3-Receptor 
AntagoniZes PDGF-Stimulated Responses,” J. Biol. Chem. 
266: 413—418 (1991) disclose expression of the PDGFR 
extracellular domain in Chinese Hamster Ovary cells using 
an ampli?able marker to increase expression. The publica 
tion discloses that the protein Was expressed in the culture 
medium at a level of 12 mg/L. The extracellular domain Was 
extensively glycosylated, and bound to PDGF-BB With an 
af?nity similar to that of the intact PDGF receptor. HoWever, 
the reference does not teach or suggest expression of a 
PDGF protein in Pichia pastoris. 
There remains a need to increase the ef?ciency of pro 
ducing proteins generally, and PDGF proteins in particular. 
It is expected that With improved production methods the 
cost of these proteins can be brought doWn and their 
availability for treating a Wide range of conditions can be 
increased. PDGF proteins are particularly implicated in as 
being useful in such applications as cancer therapy, Wound 
healing, and the treatment of gastrointestinal ulcers. 
SUMMARY OF THE INVENTION 
The present invention is directed to a method of signi? 
cantly increasing the ef?ciency of producing platelet 
derived groWth factor (PDGF) proteins, and thereby reduc 
ing their cost. The method is exempli?ed With human 
PDGF-BB, both Wild-type and mutant forms. According to 
the principles of the present invention, Wild or mutant PDGF 
is produced by transforming Pichia pastoris With a vector 
encoding the mature protein, maintaining the yeast under 
predetermined culture conditions, and isolating the protein 
from the supernatant. The PDGF proteins produced by this 
method are indistinguishable from corresponding mature 
PDGF proteins produced in humans or other systems. 
A preferred aspect of the invention is Where the PDGF 
protein assembles as a PDGF BB homodimer. More 
particularly, the PDGF BB protein is mammalian, preferably 
human, in origin. The PDGF protein can be Wild-type or a 
mutant thereof. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention permits enhanced yields and pro 
duction efficiencies of platelet-derived groWth factor 
(PDGF) proteins. The PDGF can be in either a Wild or 
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mutant form. In particular, the invention entails producing 
the PDGF by transforming Pichia pastoris With a vector 
encoding the mature protein. Preferably, the vector encoding 
the mature protein is an expression vector, Which further 
encodes a secretory peptide signal fused to the PDGF 
protein in order to facilitate secretion of the protein from the 
cells. The transformed cells are maintained under predeter 
mined culture conditions for a desired length of time, and the 
protein is then isolated from the supernatant. Whenever a 
signal peptide is employed, it is preferred that the signal is 
removed, e.g., proteolytically, either in vivo or in vitro prior 
to isolation of the mature protein so that a cleavage step can 
be avoided. As discussed herein, the PDGF proteins pro 
duced by this method are indistinguishable from correspond 
ing mature PDGF proteins produced in humans or other 
systems. 
In a preferred embodiment of the invention, the PDGF 
protein assembles as a PDGF BB homodimer. Preferably, 
the PDGF BB protein is mammalian, more preferably 
human, in origin. The PDGF protein can be Wild-type or a 
mutant thereof. Contemplated mutants of PDGF include 
single amino acid substitutions, insertions and/or deletions, 
as Well as multiple mutations. Exemplary of multiple muta 
tions are tWo, three and higher substitutions of the residues 
occurring naturally in the Wild protein. 
Culture conditions effective to express PDGF in the 
transformed yeast are exempli?ed by those set forth here 
inafter. A representative temperature range for maintaining 
the culture is 25—35° C., preferably 30° C. Arepresentative 
time for conducting the culturing is 2—4 days, preferably 3 
days. These and other parameters can be optimiZed for a 
particular scale preparation by the skilled practitioner. 
Exemplary of the present invention is the expression of 
PDGF BB using a yeast secretory signal fused to the mature 
protein. In particular, a cDNA encoding amino acid residues 
87—241 of PDGF BB Was inserted in the plasmid pPIC9 
(Invitrogen), Which contains a nucleotide sequence encoding 
the secretory signal of the yeast 0t mating factor. The 
secretory signal targets the expressed protein to the secretory 
pathWay in the endoplasmic reticulum and ultimately to the 
culture solution. The signal sequence is proteolytically 
removed prior to secretion, leaving only the mature human 
PDGF-BB as product. 
An above-described plasmid has been stably transfected 
in Pichia and a Pichia clone has been employed to obtain 83 
mg of mutant PDGF-BB (RKK—>EEE) in 5 liters of crude 
culture supernatant. Analysis of the secreted product reveals 
correct proteolytic removal of the secretory signal and 
dimeriZation into a 29—32 kDa form, Which is indistinguish 
able from the natural human product. This yield is to be 
compared With those reported elseWhere for full-length 
PDGF-BB (1.8 mg/5 L) and for a [Ser28]PDGF-BB mutant 
(18.5 mg/5 L) expressed in S. cerevisiae [17]. Thus, the yield 
of the mutant PDGF-BB obtained according to an instant 
method is approximately 40 times greater than that obtained 
for the previous full-length native protein and approximately 
4 times greater than that obtained for the previously 
described mutant. Additionally, the time required for groW 
ing the transformed yeast is reduced from 6 days to 3 days. 
A related aspect of the present invention is a Pichia 
pastoris yeast cell, and culture thereof, Wherein the R 
pastoris is transformed With a vector capable of expressing 
a PDGF protein. Preferably, the vector encodes a signal 
peptide fused to the PDGF. Preferred PDGF proteins 
encoded by the vector are those described hereinabove. 
The present invention Will noW be described With refer 
ence to certain examples Which further illustrate, but do not 
limit it. 
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EXAMPLES 
Example 1 
Expression of Recombinant Proteins in Chinese Hamster 
Ovary Cells 
The development of Chinese hamster ovary (CHO) cells 
expressing human PDGF B-chain (designated WT-RKK, for 
Wild-type loop III residues Arg160 Lys161 Lys162 or RKK) 
has been described previously [11]. Overlap extension PCR 
[12] Was used to introduce a mutation converting the three 
cationic amino acids of loop III to glutamic acid residues 
(mutant RKKQEEE). The mutant B-chain cDNAs Were 
expressed in DUX B11 cells 15 (originally described by 
Urlaub and Chasin [43]), a dihydrofolate reductase-de?cient 
variant of CHO cells, under the control of the Rous sarcoma 
virus promoter. The ?delity of all PCR syntheses Was 
veri?ed by DNA sequencing using a standard dideoxynucle 
otide termination methodology (SequenaseTM, U.S. 
Biochemicals). Methods for effecting stable transfection, 
conducting methotrexate (MTX)-induced gene ampli?ca 
tion and screening of culture supernatants for production of 
PDGF B-chain have been described previously [11]. 
Example 2 
Partial Puri?cation of WT-RKK and Mutant RKK—>EEE 
from CHO Cells 
PDGF-BB-containing culture supernatants Were collected 
over a 96 h period in serum-free DMEM as described 
elseWhere Proteins Were partially puri?ed by heparin 
agarose (Sigma; St. Louis, Mo.) chromatography (2.5><5 
cm), concentrated by ultra?ltration (Centriprep and Centri 
con 20, Amicon; Beverly, Mass.) and stored at —80° C. in the 
presence of 10% glycerol. 
Example 3 
Preparation of Wild-Type and Mutant PDGF-BB from 
Pichia pastoris 
To obtain suf?cient quantities of Wild-type and mutant 
forms of PDGF B-chain for puri?cation and analysis, 
cDNAs Were constructed by PCR and inserted into the 
expression vector pPIC9 for expression in the yeast Pichia 
pastoris (Invitrogen; Carlsbad, Calif.). Speci?cally, trun 
cated cDNAs corresponding to the mature human B-chain 
(Ser82 to Ala241) Were obtained from C. BetsholtZ, Uppsala, 
SWeden, ampli?ed by PCR, and inserted in reading frame 
With the Saccharomyces cerevisiae 0t factor prepropeptide 0t 
factor sequence according to the manufacturer’s protocol. 
The primers used for PCR Were obtained from Integrated 
DNA Technologies, Inc. (Coralville, IoWa). The 5‘-end 
primer used provided an Avr II site folloWed by nucleotides 
encoding amino acids Ser81 through Ile88. The 3‘-end primer 
contained a sequence encoding amino acids 236—241, fol 
loWed by a TAG stop codon and a Not I recognition site. The 
actual primers used are as folloWs: 
Primer 1: AAA CCT AGG AGC CTG GGT TCC CTG 
ACC ATT (SEQ ID NO: 1) 
Primer 2: TAT GCG GCC GCT AGG CTC CAA GGG 
TCT CCT T (SEQ ID NO: 2) 
The cDNAs encoding mutants RKKQSKK and 
RKK—>SSS Were synthesiZed using “megaprimer” PCR for 
site-directed mutagenesis [13]. The Pichia pastoris cells 
Were transformed by formation of spheroplasts as described 
by the supplier. 
For crude PDGF-BB preparations from Pichia pastoris, 
cultures Were groWn for 48 h in 1 L of buffered glycerol 
complex medium (BMGY: 1% yeast extract, 2% peptone, 
100 mM potassium phosphate pH 6.0, 1.34% YNB (yeast 
US 6,194,169 B1 
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nutrient broth), 4><10_5% biotin, 1% glycerol) at 30° C. With 
vigorous shaking (250 rpm). Recombinant protein expres 
sion Was induced by suspension in 100 ml of BMMY (same 
as BMGY, With a substitution of 0.5% methanol for glycerol 
as carbon source) supplemented With casamino acids, fol 
loWed by groWth for 16 h at 30° C. in 1 L baf?ed ?asks. 
Culture supernatants Were obtained by centrifugation at 
6088><g for 15 min at 4° C., and PDGF-BB Was precipitated 
by addition of crystalline ammonium sulfate (60% 
saturation) and centrifugation (20,463><g, 60 min). Pellets 
Were resuspended in 50 mM NaCl, 40 mM Hepes, pH 7.4 
and residual ammonium sulfate removed by ultra?ltration. 
Proteins Were stored at —80° C. in 50 mM NaCl, 40 mM 
Hepes, pH 7.4 containing 10% glycerol (PDGF freezing 
buffer). 
Example 4 
Radiorecentor and [3H]Thymidine Incorporation Assays for 
PDGF-BB 
Radioreceptor assays Were conducted in A204 and rat 
mesangial cells (RMC, R52 line) as described previously 
[14, 8] using 20,000 cpm of [125I]PDGF-BB (1200 
Ci/mmol; Amersham, Buckinghamshire, England) as radio 
ligand and unlabeled recombinant PDGF-BB proteins as 
competitor. Mitogenic activities of recombinant PDGF-BB 
proteins Were determined by measuring [3H]thymidine 
incorporation into cells as described 
Example 5 
In Vitro PDGF Receptor Autophosphorylation 
In vitro assays of PDGF receptor autophosphorylation 
Were conducted essentially as described [15]. A204 and R52 
cells (obtained from the American Type Culture Collection 
(AT CC) Were groWn to near con?uence on 100-mm plastic 
dishes and maintained in loW mitogenicity medium for 24 h. 
Cells Were pre-chilled at 4° C. for 60 min and then incubated 
With PDGF-BB preparations for 10 min at 4° C. Cell lysates 
Were incubated With either anti-PDGFRot or anti-PDGFRB 
IgG (Santa CruZ Biotechnologies) for 60 min at 4° C., 
centrifuged for 10 min and incubated in fresh tubes con 
taining protein A-agarose (Sigma) for 60 min at 4° C. Kinase 
assays Were performed in 25 pL kinase buffer (20 mM Tris 
HCl, 1 mM DTT, 10 mM MnCl2, pH 7.5) and 5 pCi [y-32P] 
ATP (3000 Ci/mmol) for 10 min at 30° C. Immunoprecipi 
tates Were analyZed by SDS-PAGE (6% polyacrylamide). 
Example 6 
Analysis of Heparin-Binding Activity by In Vitro Batch 
Assay 
Mixtures containing 300 pL of a 50:50 slurry of heparin 
agarose in 200 mM NaCl, 40 mM Hepes, pH 7.4 Were 
incubated With 3 pg of PDGF-BB proteins for 15 min at 23° 
C. Supernatants Were obtained by microcentrifugation and 
collected With a 23 G needle. Pellets Were Washed With 300 
pL of buffer, Which Was combined With the ?rst supernatant 
(“unbound” PDGF). Pellets Were then Washed tWice With 
150 pL of buffer containing 1 M NaCl, and supernatants 
Were pooled (high salt Wash fraction, or “bound” PDGF). 
PDGF-BB content of bound and unbound fractions Were 
determined by ELISA. 
Example 7 
Metabolic Labeling of CHO Cells With [35S]Cysteine and 
SDS-PAGE Analysis 
WT-RKK, 33 nM MTX selected, and RKKQEEE cells 
(5><105/35 mm dish) Were pulse-labeled for 30 min With 
[35S] cysteine (Amersham, 167 pCi in 0.5 mL; 401 
Ci/mmol) and chased With a 100-fold molar excess of 
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unlabeled cysteine as described [16]. One of tWo sets of cells 
Was incubated for 10 min in the presence of 1 mM suramin 
(Sigma) to release cell surface bound-PDGF-BB. 
Immunoprecipitations, SDS-PAGE and autoradiography 
Were performed as described previously [11]. 
Example 8 
Puri?cation of Pichia-Expressed PDGF-BB Proteins to 
Apparent Homogeneity. 
To obtain WT-RKK for puri?cation, the procedure 
described above Was scaled up 4-fold. The protein Was 
precipitated from supernatants With ammonium sulfate 
(60% saturation), resuspended in 40 mM Hepes pH 7.4 and 
applied to a column of phenyl-Sepharose (25x75 cm). 
PDGF-BB Was eluted With 100 mL of a 50% solution of 
ethylene glycol in 40 mM Hepes, 150 mM NaCl, 20 mM 
Tris pH 7.4. The protein Was then concentrated, exchanged 
into 40 mM Hepes pH 7.4 by ultra?ltration (Amicon) and 
applied to a column of Q Sepharose (2.5><4 cm; Pharmacia 
Fast How). The protein Was eluted With a linear 200 mL 
NaCl gradient (0.05—1.5 M), concentrated and exchanged 
into 40 mM Hepes pH 7.4 by ultra?ltration. Protein Was then 
applied to a 1x7 cm column of heparin-agarose (Sigma), 
equilibrated With 100 mM NaCl, 40 mM Hepes pH 7.4 and 
eluted With 600 mM NaCl. PDGF-BB Was concentrated, 
applied to a 1x8 cm column of Sephadex G-25 (Sigma) 
equilibrated With 0.5 M urea, 10 mM glycine, pH 3.0, and 
further puri?ed by Superose 12 FPLC (10><30 Pharmacia; 
PiscataWay, N.J.), as described elseWhere [17]. 
The Pichia clone expressing RKK—>EEE Was groWn in 
large-scale (14 L) under conditions optimiZed for high 
requirements of methanol and 02, using a NeW Brunswick 
Microferm Fermenter. Five liters of cleared culture super 
natant Was obtained by Sharples centrifugation, yielding 
approximately 83 mg of PDGF-BB. After precipitation of 
protein from the culture supernatant With 80% ammonium 
sulfate, one-sixth of the precipitate Was subjected to phenyl 
Sepharose chromatography (25x18 cm). The protein Was 
eluted in 300 ml of 50% ethylene glycol, Which Was con 
centrated and exchanged into 50 mM NaCl, 10 mM 
Na2HPO4, pH 7.4 by ultra?ltration. The protein Was applied 
to a 5x5 column of Mono-Q at a How rate of 1 mL/min and 
eluted With a linear 200 ml gradient (0.15—1 M NaCl, 10 mM 
Na2HPO4). It Was further puri?ed by Superose 12 FPLC 
(10x30) in a buffer of 150 mM NaCl, 10 mM Na2HPO4, pH 
7.4 (?oW rate 0.4 mL/min). PDGF-containing fractions Were 
pooled, concentrated and stored in PDGF freeZing buffer at 
—80° C. until further use. Protein concentrations Were deter 
mined by amino acid compositional analysis. 
Example 9 
Circular Dichroism Spectrophotometry. 
Spectra of puri?ed RKK—>EEE Were recorded in 190—260 
nm range using a Jasco 600 CD spectrometer and a 0.01 cm 
path length circular demountable cell. The protein Was 
analyZed at a concentration of 0.20 mg/mL in 10 mM acetic 
acid, pH 3.2. The mean residue M, of RKK—>EEE Was 
estimated as 235, using an estimate of Mr for the PDGF-BB 
dimer of 26,000. Estimates of secondary structure Were 
derived using softWare supplied by Jasco, Which is based 
upon the method of Yang et al. [18]. 
Example 10 
Stable Transfection of Human Glioblastoma (U87) Cells 
With PDGF Expression Vectors and Tumor GroWth in Athy 
mic Nude Mice. 
Transfections and stable expression in the human glio 
blastoma cell line U87 Were performed using a liposomal 
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reagent (LipofectinTM) (Gibco/BRL; Gaithersburg, Md.), as 
described [19]. Cells Were cultured in 162 cm2 ?asks in 
complete DMEM. On the day of injection, cells Were 
removed by trypsiniZation, rinsed tWice With Hanks bal 
anced salt solution (HBSS, Without phenol red; Gibco/ 
BRL), and resuspended in 300 pL HBSS. Cells (107) from 
exponentially growing cultures of stable U87 transfectants 
Were injected subcutaneously betWeen the scapulae of 
9-Week-old athymic nude mice (Harlan Sprague-DaWley, 
nu/nu) using a 1 cc tuberculin syringe equipped With a 
23-gauge needle. TWo-dimensional measurements of tumors 
Were obtained With vernier calipers. 
RESULTS 
Mutagenesis of the Arg159 Lys160 Lys161 Sequence of the 
PDGF B-chain Disrupts the Ability to Bind PDGF ot- and 
[3-receptors and Induce Receptor Autophosphorylation. 
Cationic amino acid residues located Within the loop III 
region of the B-chain (Arg159 Lys160 Lysl?l, or RKK) Were 
substituted With the anionic amino acid glutamate or polar, 
uncharged serine residues to analyZe the role of this region 
in B-chain function. In addition to the Wild type (WT-RKK), 
three mutant proteins Were expressed in the methylotropic 
yeast Pichia pastoris for functional and structural analyses. 
TWo of the mutations consisted of substitutions of the Arg159 
Lys160 Lys161 sequence at each residue With either glutamate 
(Arg159 Lys160 Lys161 to Glu159Glu16OGlu161, or 
RKKQEEE) or serine (RKK—>SSS), While the third con 
tained a single Arg159 to Ser159 substitution (RKKQSKK). 
Serine Was selected due to its non-charged, but hydrophilic 
character, Which Was predicted to minimize structural dis 
ruption of the external loop III domain. To permit indepen 
dent assessment of the role of the RKK motif for binding to 
PDGF ot- and [3-receptors, effects of these mutations Were 
evaluated both in A204 cells, Which express exclusively the 
ot isotype [20] and R52 cells, Which express the [3 isotype 
[11]. 
Compared to the WT-RKK protein, the RKKQEEE 
mutant Was markedly impaired (by a factor of 400) in its 
ability to compete With [125I]PDGF-BB for binding to both 
A204 (FIG. 1A, Table I) and R52 cells (FIG. 1B, Table I), 
indicating that one or more residues in the RKK sequence 
are involved in binding of PDGF-BB to both ot- and 
[3-receptors. In addition, the RKK—>SSS mutant exhibited a 
signi?cant decrease in slope and a slight decrease in af?nity 
(factor of 3) When analyZed in R52 cells, although no effect 
of this mutation Was seen on binding to A204 cells. This 
contrast reveals a subtle difference in the nature of the 
interaction of the RKK sequence With the tWo different 
receptor subclasses. Binding of the RKKQSKK mutant to 
PDGF receptors Was unaffected in either A204 or R52 cells, 
suggesting a lack of a signi?cant role for Arg160 in the 
interaction betWeen PDGF-BB and either receptor isotype. 
To investigate Whether the ability of PDGF-BB to activate 
PDGF receptors Was similarly affected by disruption of the 
cationic region, the abilities of WT-RKK and RKKQEEE to 
induce receptor autophosphorylation in vitro Were assessed 
in A204 and R52 cells. WT-RKK elicited dose-dependent 
autophosphorylation of 170 kDa PDGF receptor species in 
both A204 cells and R52 cells. In A204 cells, hoWever, the 
RKKQEEE mutant Was much less potent than Wild type, 
With concentrations as high as 3 pg/mL required to elicit 
detectable ot-receptor autophosphorylation, While no auto 
phosphorylation of [3-receptors Was obtained in R52 cells. 
These observations correlate With the reduced receptor bind 
ing activity of RKKQEEE, indicating that disruption of the 
RKK motif With negatively charged glutamate residues also 
interferes With its ability to activate both ot- and [3-receptors. 
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The Receptor Binding-Defective Mutant RKKQEEE is 
Mitogenically Active. 
Mitogenic activities of Wild-type and mutant B-chain 
proteins expressed in Pichia pastoris Were assessed by 
[3H]-thymidine incorporation assay in NR6 cells, a variant 
of the SWiss 3T3 cell line Which expresses primarily 
ot-receptors A steep dose-response curve Was observed 
With WT-RKK With an ED5O of 52 ng/mL (Table I). The 
RKKQSKK and RKK—>SSS mutants exhibited slightly 
higher potencies than WT-RKK, While, surprisingly, the 
potency of the RKKQEEE mutant Was identical to that of 
WT-RKK. To exclude the possibility of interference from 
potential contaminating mitogens in Pichia pastoris culture 
supernatants, WT-RKK and RKK—>EEE Were puri?ed to 
apparent homogeneity prior to analysis and identical results 
Were obtained. Similar results Were obtained in [3-receptor 
expressing R52 cells. The ability of the receptor binding 
defective mutant RKKQEEE to fully stimulate DNA syn 
thesis suggests that PDGF-BB may stimulate entry of cells 
into S phase through a mechanism distinct from high affinity 
binding to PDGF receptors. 
Alteration of the RKK Sequence Interferes With Binding of 
PDGF-BB to Heparin. 
During initial attempts to purify the RKKQEEE mutant 
a dramatic loss in binding to heparin-agarose Was noted. 
Because of the physiologically important role of heparin 
containing proteoglycans in the association of PDGF-BB 
and the so-called “long” form of PDGF-AA With the extra 
cellular matrix [20,21], binding of the loop III mutants to 
heparin Was examined in further detail. To quantify heparin 
binding activity of these proteins, an in vitro heparin 
agarose binding assay Was developed. Employing buffer 
conditions that Were near-physiological With respect to pH 
and NaCl concentration, nearly 100% of WT-RKK bound to 
the matrix. HoWever, binding of RKKQEEE and 
RKK—>SSS Were signi?cantly impaired, With only 38% of 
each protein appearing in the bound fraction. The 
RKKQSKK mutant also exhibited decreased heparin 
binding (74% bound), implicating Arg160 in the binding 
interaction. Taken together, these results strongly suggest 
that the loop III region contributes to the heparin binding 
interface of the PDGF-BB molecule. 
The RKKQEEE Mutant is Secreted as Non-Cell-Associated 
Species of 29—32 kDa. 
The decreased heparin-binding activity of RKK—>EEE in 
vitro suggested that the protein may be altered in its asso 
ciation With heparan sulfate proteoglycans (HS-PGs) in the 
extracellular matrix. PDGF-BB has been shoWn to associate 
ef?ciently With the cell surface [22,23], probably via inter 
actions With HS-PGs [24, 25], and the cell surface 
associated form is releasable With the heparin-like polyanion 
suramin. Thus, kinetics of cell surface association and 
secretion of PDGF-BB Were analyZed by a pulse-chase 
approach in CHO cells expressing WT-RKK or RKKQEEE. 
As shoWn previously [22,11], WT-RKK appears on the cell 
surface Within 1 h in a suramin-releasable form as a doublet 
of 34 and 35 kDa (p34/35) that peaks Within 3 h and 
disappears by 24 h. Only trace amounts of non-cell 
associated WT-RKK (p29—32) Were seen by 24 h of chase. 
No signi?cant change in suramin-releasable p34/35 Was 
observed for the RKK—>EEE mutant over the 24 h course of 
the experiment. HoWever, a slight increase Was apparent in 
the amount of mutant p34/35 appearing in the culture 
medium at 6 and 24 h of chase, suggesting an impairment in 
cell surface association. Moreover, a marked increase Was 
seen in release of p29—32 into the culture supernatant at 6 
and 24 h, consistent With an important role of the RKK motif 
in stabiliZing association With the cell surface. 
US 6,194,169 B1 
9 
Analysis of RKK—>EEE Mutant Structure by Circular 
Dichroism Spectroscopy. 
To con?rm that the diminished receptor binding and 
heparin binding activities of the RKKQEEE mutant Were 
not a function of major alterations in secondary structure, 
Pichia-expressed RKK—>EEE Was puri?ed to homogeneity 
as described above and analyZed by circular dichroism (CD) 
spectroscopy. Purity and molecular Weights of recombinant 
protein preparations Were assessed by SDS-PAGE under 
nonreducing and reducing (dimer-dissociating) conditions 
prior to CD analysis. In the absence of the reducing agent 
dithiothreitol, WT-RKK migrated as a complex of 28—30 
kDa species, very similar to the species expressed in CHO 
cells [22], With trace amounts of a 15 kDa species observed 
in the preparation. The 28—30 kDa complex Was converted 
upon reduction to a predominant 15.5 kDa monomeric form. 
The pattern of RKK—>EEE molecular Weight species 
observed under non-reduced and reduced conditions Was 
nearly identical to that seen With WT-RKK, With the excep 
tion of a trace of a non-reducible 24 kDa contaminant and 
equal amounts of reduced p155 and a p14 species. The 
appearance of the monomeric p14 species of RKK—>EEE 
Was possibly the result of increased proteolytic cleavage, 
secondary to the high yeast culture density and longer 
collection time prior to harvest. 
The CD spectrum obtained With the RKKQEEE protein 
Was essentially identical to that reported for human PDGF 
BB expressed in Saccharomyces cerevisiae [24]. The spec 
trum Was characteriZed by a signi?cant shoulder at 228 nm 
and strongly positive ellipticity at 190 nm, both of Which 
Were consistent With a high percentage of [3-sheet structure 
in the molecule, estimated to be approximately 50%. The 
minimum center at 203 nm Was indicative of high random 
coil content (43%), and the molecule contained only a small 
percentage of ot-helical residue content (7%). These second 
ary structure estimates are also in close agreement With 
those obtained previously for PDGF-BB [24], as Well as 
With the PDGF-BB structure derived directly by X-ray 
diffraction [22]. The lack of any detectable signi?cant dis 
ruption in secondary structure for the RKK—>EEE protein 
strongly suggests that the impairment in binding to receptors 
and heparin, as Well as the increased secretion of the protein, 
Were not the result of major structural perturbations in the 
molecule. 
Loop III Mutants of the PDGF A- and B-chains Exhibit 
Dominant-Negative Activity. 
The receptor binding-de?cient RKKQEEE mutants of 
the PDGF A-chain [8] and B-chain remain able to dimeriZe, 
suggesting a potential for dominant-negative activity via 
inactivation of endogenous PDGF monomers. The human 
glioblastoma cell line U87 Was employed for assessment of 
dominant-negative activity, since a PDGF autocrine loop 
drives its malignant groWth, even in the absence of exog 
enous groWth factors such as serum [19]. U87 cells Were 
stably transfected With cDNAs encoding Wild-type A- and 
B-chains, as Well as their RKKQEEE mutant counterparts, 
as described above. When groWth characteristics of trans 
fected U87 clones Were assessed in cell culture, one of the 
A-chain RKKQEEE expressing clones (AC'"8.1), exhibited 
a dependence upon exogenous groWth factor (i.e., fetal 
bovine serum) consistent With disruption of the PDGF 
autocrine loop by this construct. 
The effects of RKKQEEE mutant expression on malig 
nant groWth of U87 cells Were also evaluated in athymic 
nude mice. Neomycin-resistant controls (Neo) all developed 
prominent tumors that Were detected Within approximately 
seven days and reached an average siZe of 3 cm3 Within 30 
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d. The groWth of tumors from clones overexpressing either 
A-WT-RKK or B-WT-RKK Was not signi?cantly different 
from that of Neo controls. HoWever, overexpression of 
either A-RKKQEEE or B-RKK—>EEE almost totally cur 
tailed tumor groWth in vivo. In tWo of three A-RKK—>EEE 
clones examined (8.1 and 8.4), no tumor development Was 
observed over a 30 d time course, While only small tumors 
(<1 cm3) could be observed by 40 d in the third clone (7.1). 
Similar results Were obtained With the three B-RKKQEEE 
clones evaluated. Taken together, these results indicate 
dominant-negative activity of RKKQEEE mutants of the 
PDGF A- and B-chains, and support previous evidence [19] 
for a role of PDGF in mediating groWth of U87 cells in vitro 
and in vivo. 
DISCUSSION 
Conversion of the RKK sequence to triglutamate 
(RKKQEEE) resulted in a marked loss in the ability to bind 
PDGF receptors and induce receptor autophosphorylation . 
Substitutions of the RKK sequence With the polar, 
uncharged amino acid serine Were not as disruptive to 
receptor binding as glutamate substitutions, although con 
version of all three residues to serine resulted in a small 
decrease in binding to [3-receptors and a signi?cant decrease 
in the slope of the [3-receptor binding curve. The ability of 
serine to partially substitute for the RKK sequence suggests 
that its hydroxyl moieties can form stabiliZing bonds (i.e., 
hydrogen bonds) With receptor. The marked inhibitory effect 
of glutamate residues suggests an inability of this amino acid 
to form such bonds, or possibly electrostatic repulsion With 
receptor. Consistent With this notion is the observation that 
substitution at Lys161 With uncharged, non-polar alanine 
impairs ot-receptor binding by a factor of 4—10, While 
substitution With negatively charged aspartate reduces bind 
ing to both ot- and [3-receptors by a factor of>10 [10]. 
Previous studies have indicated that cationic amino acids 
encoded by the sixth exons of the PDGF A- and B-chains 
play an important role in the abilities of PDGF-AA and -BB 
to remain associated With the cell surface and extracellular 
matrix via binding interactions With heparan sulfate pro 
teoglycans (HS-PGs) [20,28]. This association is mediated 
by interactions With the heparin-like glycosaminoglycan 
(GAG) moieties of the HS-PG [20,29—31] and is considered 
to involve electrostatic interactions betWeen the cationic 
amino acids in the PDGFs and negatively charged groups of 
the polysaccharide. The biological importance of this inter 
action is indicated by the inhibition of PDGF-induced mito 
genesis With either heparin-like GAGs or cationic peptides 
derived from the region encoded by exon 6 of the A-chain 
[28,30]. The current study suggests, hoWever, that regions 
other than the exon 6-encoded sequence, such as the loop III 
domain, contribute to heparin binding activity of the 
B-chain. The partial loss in heparin binding observed With 
the RKKQSKK mutant indicates a speci?c role for Argl?o, 
While the more marked inhibition resulting from simulta 
neous substitutions at all three residues (RKK—>EEE and 
RKKQSSS) strongly suggests that one or both of the 
remaining residues (Lys161 and Lys162) also contribute to the 
binding interaction. 
A role of the RKK sequence for mediating binding 
betWeen the cell-associated 34/35 kDa species and the 
extracellular matrix is supported by pulse-chase analyses of 
CHO cells that express the RKKQEEE mutant. The accu 
mulation of the 29—32 kDa species of RKKQEEE, and to a 
lesser extent, the 34/35 species in the culture supernatant 
suggests a loWer affinity of the mutant for extracellular 
matrix. These data indicate that the previously characteriZed 
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C-terminal retention domain of the B-chain, Which remained 
intact in the 34/35 species of the RKK—>EEE mutant, is 
insufficient to mediate full association of PDGF-BB With the 
cell surface and extracellular matrix. Taken together, the in 
vitro heparin binding and pulse-chase studies suggest that 
the heparin-binding interface of the PDGF-BB molecule is 
comprised of cationic amino acid residues found in both the 
loop III and C-terminal regions. 
The lack of impairment in mitogenic activity of the 
receptor binding-de?cient RKKQEEE mutant Was 
unexpected, especially since the analogous RKK—>EEE 
mutant of the A-chain is equally impaired in its receptor 
binding and mitogenic activities Dissociation of binding 
and mitogenesis is precedented, hoWever, in studies of 
PDGF and other groWth factors. For example, Clements et 
al. [36] demonstrated that substitution for Arg108 With 
glutamate in the PDGF B-chain signi?cantly impaired its 
ability to bind receptor (by a factor of approximately 10) and 
to stimulate inositol lipid turnover (by a factor of >35), but 
did not affect mitogenic activity. In addition, a recent study 
has demonstrated that FGF can induce mitogenic signaling 
in the presence of high concentrations of heparin that 
interfere With high-af?nity receptor binding [37]. 
HoW can mitogenic signaling be elicited by groWth fac 
tors Without high affinity binding to receptors? A PDGF 
receptor-independent pathWay for mitogenic signaling is 
unlikely, since many studies have demonstrated the neces 
sity of receptor tyrosine kinases for mitogenesis induced by 
PDGF [38], FGF [37] and other ligands. A second 
possibility, that the RKKQEEE protein can fully stimulate 
mitogenesis through a minimal degree of receptor 
occupancy, also seems improbable since the ED5O for mito 
genesis of the mutant is unaltered. In a study of FGF/FGF 
receptor interactions [39], a model termed “transient recep 
tor binding” is proposed in Which a low affinity ligand may 
elicit mitogenic signaling if the on-rate of binding is sig 
ni?cant. 
Overexpression of PDGF A- and B-chains harboring the 
RKKQEEE mutation inhibited focus formation of U87 
astrocytoma cells in culture, With the A-chain RKK—>EEE 
mutant conferring a dependence upon exogenous serum 
groWth factors for groWth. The groWth inhibitory activities 
of both the A-chain and B-chain RKKQEEE mutants on 
U87 tumors in athymic nude mice suggest that high affinity 
binding, mediated in part by interaction betWeen the RKK 
domain and PDGF receptor, is required for maintenance of 
the malignant phenotype of these cells. The efficacy of these 
and other dominant-negative PDGF mutants [40,19,15] sug 
gest possible avenues for gene therapy approaches to astro 
cytoma and other cancers for Which autocrine and paracrine 
activities of PDGF may play a role. 
The present invention has been described With reference 
to certain examples for purposes of clarity and understand 
ing. It should be understood hoWever that the invention can 
be practiced With modi?cations and/or improvements With 
out departing from the scope of the appended claims and 
their equivalents. 
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TABLE 1 
Biological activity of PDGF-BB mutants 
RRA: ICSD ng/ml Mitogenesis 
Protein or [5 ED5U (ng/ml) 
WT-RKK 9.2 4.0 52 
RK —> SKK 2.3 2.2 28 
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TABLE l-continued 
Biological activity of PDGF-BB mutants 
RRA: ICED ngZml Mitogenesis 
Protein or [5 ED5U (ng/ml) 
RKK —> SSS 6.5 13.8 12 
RKK —> EEE 4040 1240 52 
Data Were derived from radioreceptor (RRA) and mitogenesis assay data. 
IC5O and ED5D values Were calculated using the four-parameter logistic 
equation described by the ALLFIT algorithm [42]. 
TABLE 2 
Secondary structure for Wild-type and RKK —> EEE mutant 
PDGF-BB obtained by circular dichroism 
Percentage of molecules in each 
Structure (%) PDGF-BB RKK —> EEE 
Helix 4.0 7.4 
Beta 51.0 50.0 
Random 45.0 42.6 
As reported by Craig et al. (1992) for circular dichroism PDGF-BB 
expressed in Saccharomyces cerevisiae 
What is claimed is: 
1. A method of producing a platelet-derived growth factor 
PDGF BB or mutant thereof comprising: 
transforming Pichia pastoris yeast With an expression 
vector encoding the PDGF BB or mutant thereof fused 
to a secretory signal, Wherein said PDGF BB is a PDGF 
BB homodimer and said mutant has mitogenic activity 
similar to that of said PDGF BB homodimer; 
maintaining the transformed yeast under culture condi 
tions effective to express the PDGF BB or mutant as the 
mature protein in the culture supernatant; and 
isolating the protein from the supernatant. 
2. The method of claim 1, Wherein the PDGF is human in 
origin. 
3. The method of claim 1, Wherein the PDGF is Wild-type. 
4. The method of claim 1, Wherein the PDGF is a mutant 
of Wild-type. 
5. The method of claim 1, Wherein the PDGF BB 
homodimer is the human 29—32 homodimer. 
6. The method of claim 1, Wherein the secretory signal is 
the secretory signal of yeast (X mating factor. 
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7. The method of claim 1, Wherein the expression vector 
is pPIC9 modi?ed to contain a nucleotide sequence encod 
ing PDGF. 
8. A culture of Pichia pastoris transformed With an 
expression vector encoding a PDGF BB protein or mutant 
thereof fused to a signal peptide, Wherein said PDGF BB is 
a PDGF BB homodimer and said mutant has mitogenic 
activity similar to that of said PDGF BB homodimer. 
9. The culture of claim 8 Wherein the PDGF is human in 
origin. 
10. The culture of claim 8, Wherein the PDGF is Wild 
type. 
11. The culture of claim 8, Wherein the PDGF BB 
homodimer is the human 29—32 homodimer. 
12. The culture of claim 8 Wherein the signal peptide is the 
secretory signal of yeast (X mating factor. 
13. The culture of claim 8, Wherein the expression vector 
is pPIC9 modi?ed to contain a nucleotide sequence encod 
ing PDGF. 
14. The method according to claim 1, Wherein said mutant 
is altered at the Arg15 9, Lys160 and Lys161 residues With an 
anionic or polar, uncharged amino acid. 
15. The culture according to claim 8, Wherein said mutant 
is altered at the Arg15 9, Lys160 and Lys161 residues With an 
anionic or polar, uncharged amino acid. 
16. The method according to claim 14, Wherein said 
amino acid is glutamic acid or serine. 
17. The method according to claim 16, Wherein said 
mutant comprises the sequence 
Glu159, Glu160, Glu161; 
Ser159, Ser160, Ser161; or 
Ser159, Lys160, Lys161. 
18. The culture according to claim 15, Wherein said amino 
acid is glutamic acid or serine. 
19. The culture according to claim 18, Wherein said 
mutant comprises the sequence 
Glu159, Glu160, Glu161; 
Ser159, Ser160, Ser161; or 
Ser159, Lys160, Lys161. 
* * * * * 
